Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PALI Relative to the S&P 500

PALI Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Palisade Bio, Inc. (NASD:PALI) seasonal charts above shows that a Buy Date of November 22 and a Sell Date of February 17 has resulted in a geometric average return of 2.97% above the benchmark rate of the S&P 500 Total Return Index over the past 16 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 16 years by an average of 102.97% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

To download PALI seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PALI